Increasing knowledge of intertumor heterogeneity, intratumor heterogeneity, and cancer
evolution has improved the understanding of anticancer treatment resistance. A better …

Big data problems are becoming more prevalent for laboratory scientists who look to make
clinical impact. A large part of this is due to increased computing power, in parallel with new …

Background Improving our understanding of cancer and other complex diseases requires
integrating diverse data sets and algorithms. Intertwining in vivo and in vitro data and in …

Quantitative systems pharmacology (QSP), a mechanistically oriented form of drug and
disease modeling, seeks to address a diverse set of problems in the discovery and …

The development of an in silico approach that evaluates and identifies appropriate treatment
protocols for individuals could help grow personalized treatment and increase cancer …

Mechanistic models are built using knowledge as the primary information source, with well-
established biological and physical laws determining the causal relationships within the …

BACKGROUND From a clinical pharmacology perspective, oncology drug development is
associated with unique challenges compared with other therapeutic areas. 1, 2 Clinical …

Recently, therapeutic drug monitoring of 5-fluorouracil (5-FU), the key chemotherapeutic
drug for colorectal cancer, has been applied in daily clinical practice and has contributed …

Background: Although surgical resection is the only potentially curative treatment for
pancreatic cancer (PC), long-term outcomes of this treatment remain poor. The aim of this …

Quantitative characterization of evolving tumor resistance under targeted treatment could
help identify novel treatment schedules, which may improve the outcome of anti-cancer …